Shanghai Fosun Pharmaceutical (Group) , Ltd. Receivables

Shanghai Fosun Pharmaceutical (Group) , Ltd. (600196.SS) currently reports a receivables of $9.8B as of June 2026. That compares with $10B in the prior-year period — down 1.3% year over year. Use the charts on this page to explore Shanghai Fosun Pharmaceutical (Group) , Ltd.'s receivables history and peer comparisons.

Shanghai Fosun Pharmaceutical (Group) , Ltd.'s receivables decreased from $10B to $9.8B — a 1.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Shanghai Fosun Pharmaceutical (Group) , Ltd. reported $9.8B in receivables as of June 2026. That compares with $10B in the prior-year period — down 1.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $9.8B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Shanghai Fosun Pharmaceutical (Group) , Ltd., and consider following 600196.SS for alerts when major investors trade the stock.